Acadian Asset Management
CMPX icon

Acadian Asset Management’s Compass Therapeutics CMPX Stock Holding History

Acadian Asset Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.54M Buy
+1,161,231
New +$3.43M ﹤0.01% 1015
2026
Q1 		– Sell
-4,867
Closed -$26K – 2052
2025
Q4 		$26K Buy
+4,867
New +$22.5K ﹤0.01% 1881

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Acadian Asset Management's CMPX Position: Q2 2026 in Review

Acadian Asset Management opened a new position in Compass Therapeutics (CMPX) in Q2 2026: 1,161,231 shares worth $2.54M. The stake represents ﹤0.01% of the portfolio and ranks #1015 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in CMPX as recently as Q4 2025.

Acadian Asset Management first reported a position in CMPX in Q4 2025 and has held it in 2 quarters since. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Acadian Asset Management held 1,161,231 shares of Compass Therapeutics worth $2.54M as of Q2 2026.
  • Compass Therapeutics was a new Acadian Asset Management position in Q2 2026.
  • Compass Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1015 holding.
  • Acadian Asset Management first reported a position in Compass Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.